Farxiga Switching Protocols: How to Switch From or To Dapagliflozin and Other SGLT2 Inhibitors

What this page answers, and what it does not

This page is written for clinicians and patients navigating a change from one SGLT2 inhibitor to another, most commonly dapagliflozin (Farxiga), empagliflozin (Jardiance), canagliflozin (Invokana), or ertugliflozin (Steglatro). It does not replace an individualized medication reconciliation with the prescribing clinician, and it does not provide a dose for any specific patient. Dosing and switch timing should be confirmed against the current FDA label and the prescriber's own assessment of renal function, volume status, and indication.

The direct answer

Every FDA-approved SGLT2 inhibitor blocks the same transporter (SGLT2) in the proximal renal tubule, so switching within the class is a receptor-level substitution rather than a change in mechanism, and no washout period is specified in the dapagliflozin label. What differs across the class is which agent has trial evidence and FDA approval tied to a given clinical problem: dapagliflozin and empagliflozin currently carry the broadest indication sets (type 2 diabetes, heart failure across ejection fraction categories, and chronic kidney disease), while canagliflozin and ertugliflozin do not have FDA-approved heart failure indications. A switch driven by cost or formulary access is mechanistically low-risk; a switch driven by a new heart failure or CKD diagnosis is really an indication-matching decision, and it should be documented as such.

Mechanism: why a class switch is pharmacologically straightforward

Dapagliflozin blocks SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. This same mechanism is shared by empagliflozin, canagliflozin, ertugliflozin, and (with an added SGLT1 component) sotagliflozin. Because the target is identical, a same-day substitution between agents does not require a taper or gap, unlike drug classes where receptor affinity, half-life, or active metabolites complicate a transition.

SGLT2 inhibitors also reduce intraglomerular pressure by restoring tubuloglomerular feedback, an effect that is consistent across the class and is thought to underlie the renal-protective signal seen in outcome trials. Pharmacology reviews describe differing degrees of SGLT2-versus-SGLT1 selectivity across agents, with canagliflozin generally considered less SGLT2-selective than dapagliflozin or empagliflozin, which may explain a somewhat higher rate of GI symptoms with canagliflozin. Exact selectivity ratios vary by assay and are not repeated here as precise numbers; a clinician wanting the specific figures should check the primary pharmacology literature directly rather than relying on secondary summaries.

Where dapagliflozin sits relative to other SGLT2 inhibitors

The trials that established cardiorenal benefit were agent-specific: DAPA-HF and DAPA-CKD studied dapagliflozin, EMPA-REG OUTCOME and EMPEROR-Reduced studied empagliflozin, and CREDENCE and CANVAS studied canagliflozin. Each trial reported a relative risk reduction in its primary composite endpoint compared with placebo, generally in the range widely reported as 20 to 40 percent depending on the trial and endpoint definition. Because the exact hazard ratios and confidence intervals depend on the specific trial and outcome definition, anyone documenting these figures for clinical or regulatory purposes should confirm them against the original trial publication rather than a secondary source, including this one.

Approved indications, current as of this writing (verify against each drug's current FDA label, since indications and label language change over time):

If a patient on canagliflozin or ertugliflozin develops heart failure, switching to dapagliflozin or empagliflozin moves them to an agent with FDA-approved heart failure indication support; staying on canagliflozin or ertugliflozin for a new heart failure diagnosis is not aligned with the approved label for that indication, even though the underlying mechanism is shared across the class.

Direct switching protocol

No pharmacokinetic washout is required when switching between SGLT2 inhibitors, and the dapagliflozin FDA label does not specify a transition interval. This section describes common clinical practice, not a step mandated by the label.

Step 1: Confirm the indication and target dose

For type 2 diabetes, dapagliflozin is typically dosed at 5 mg or 10 mg once daily. For heart failure or CKD indications, 10 mg once daily is the dose used in the pivotal trials and reflected in the label. A patient switching from a higher-potency glycemic dose of another agent (for example, canagliflozin 300 mg) to dapagliflozin 10 mg may see a small glycemic gap; this is a reasonable clinical trade-off but should be documented and followed up.

Step 2: Pre-switch checks

• eGFR. Confirm current renal function. Dapagliflozin is not recommended for the glycemic indication below the eGFR threshold specified in the label; for HF and CKD indications, the label permits use at lower eGFR values under clinical supervision. Confirm the current threshold against the label rather than relying on a remembered number, since label language has changed as trial data accumulated.
• Serum potassium. SGLT2 inhibitors have a modest potassium-raising effect in patients with reduced kidney function; a recent potassium level is reasonable before the switch in anyone with CKD.
• Ketone assessment if symptomatic. If the patient reports nausea, vomiting, or unusual fatigue, rule out euglycemic diabetic ketoacidosis (DKA) before proceeding with the switch, regardless of blood glucose level.
• Blood pressure and volume status, especially in patients on loop diuretics (see below).

Step 3: Execute the substitution

Stop the current agent at the end of the existing supply and start dapagliflozin the next morning. There is no established benefit to overlapping two SGLT2 inhibitors, and doing so doubles tubular SGLT2 blockade without a demonstrated additive glycemic or cardiorenal benefit, while plausibly increasing volume-depletion and DKA risk. This overlap risk is a mechanistic inference from how the drugs work, not something directly measured in a dedicated overlap-safety trial; it is a reasonable basis for avoiding overlap, not a quantified risk figure.

Step 4: Post-switch monitoring

• HbA1c around 12 weeks if the switch involves a dose or potency change for the glycemic indication
• eGFR around 4 weeks in CKD patients; an early dip of roughly 10 to 15 percent is a recognized hemodynamic response to SGLT2 inhibition and is not itself a reason to stop, though a much larger or symptomatic drop warrants evaluation
• Weight and volume status at the first follow-up visit
• Screening for genital mycotic infection and urinary tract infection symptoms at routine visits, since these are class-wide effects rather than agent-specific ones

Switching to dapagliflozin from a specific agent

From empagliflozin. Both are approved for type 2 diabetes, HFrEF, HFpEF, and CKD, and 10 mg to 10 mg is treated as a like-for-like substitution in practice. Most such switches are driven by formulary or cost pressure rather than a clinical problem with the prior agent.

From canagliflozin. This switch commonly arises when a patient develops heart failure, since canagliflozin does not carry an FDA-approved heart failure indication. Canagliflozin also carries a lower-limb amputation signal identified in the CANVAS trial; subsequent analyses have been mixed on how much this attenuates the concern, and a clinician managing a patient with peripheral arterial disease may reasonably weigh this history when choosing a destination agent, while recognizing that no trial has directly measured outcomes for patients who switch away from canagliflozin.

From ertugliflozin. Ertugliflozin has no FDA-approved heart failure or CKD indication and its cardiovascular outcomes trial did not demonstrate a significant reduction in major adverse cardiovascular events versus placebo. A patient on ertugliflozin who develops heart failure or progressive CKD is a candidate for dapagliflozin or empagliflozin on indication grounds, not just formulary grounds.

From sotagliflozin. Sotagliflozin is a combined SGLT1/SGLT2 inhibitor approved for heart failure, with trial evidence specifically in patients recently hospitalized for worsening heart failure. Switching to dapagliflozin means losing the SGLT1 component; there is no dapagliflozin trial in that exact acute post-hospitalization population, so this is a case where documenting the clinical rationale (typically formulary access or GI tolerability) matters more than usual.

Special populations

Chronic kidney disease

Confirm eGFR reasonably close to the time of the switch. An early eGFR dip after starting any SGLT2 inhibitor is an expected hemodynamic effect and, on its own, is not a reason to discontinue; a much larger drop, or one accompanied by symptomatic volume depletion, warrants reassessment. Guideline bodies addressing diabetes and CKD management have incorporated SGLT2 inhibitors into their recommendations for patients with type 2 diabetes and reduced eGFR; the specific eGFR range in current guidance should be checked against the most recent version of that guideline rather than assumed.

Heart failure patients on loop diuretics

SGLT2 inhibitors add a natriuretic effect on top of loop diuretic therapy. In a patient on a meaningful diuretic dose, or one with borderline blood pressure or orthostatic symptoms, it is reasonable to reassess the diuretic dose around the time of the switch rather than simply substituting the SGLT2 inhibitor and leaving everything else unchanged. This is a matter of individualized clinical judgment, not a labeled instruction.

Type 1 diabetes (off-label)

Dapagliflozin is FDA-approved for type 2 diabetes, not type 1. Use in type 1 diabetes is off-label and carries a materially higher DKA risk because these patients lack endogenous insulin to suppress ketogenesis. Professional diabetes guidance has described SGLT2 inhibitor use in selected type 1 diabetes patients as something that may be considered only under specialist supervision with rigorous ketone monitoring; this is not a routine or first-line use, and switching within the class in this population should carry the same off-label caveat and the same mandatory ketone monitoring as initiation.

Perioperative and sick-day management

FDA safety communications addressing SGLT2 inhibitors as a class have recommended holding the drug for several days before elective surgery or during prolonged fasting or serious illness, given the DKA risk in that setting. If a patient is in the middle of a switch when an illness or planned surgery arises, the same hold applies to whichever SGLT2 inhibitor is active. Resume the new agent, not the discontinued one, once the patient is eating normally and the acute issue has resolved.

Safety signals specific to switching, not initiation

Most switches in a stable patient are uneventful, but three issues are worth specific attention at the moment of transition rather than only at initiation.

Euglycemic DKA. DKA risk with SGLT2 inhibitors is a class effect tied to the mechanism, not to a specific agent, and the highest-risk period is generally described as the early weeks after starting SGLT2 inhibitor therapy for the first time. A patient who has tolerated one SGLT2 inhibitor for an extended period and is switching to another is not re-entering that same initiation-risk window in the same way, though acute illness, reduced oral intake, or a recent dose change can still precipitate DKA regardless of how long the patient has been on the class.

Urinary tract infection. SGLT2 inhibitors as a class are associated with an increased rate of UTIs compared with placebo. Screen for active symptoms before starting the new agent and treat any active infection first.

Fournier's gangrene. The FDA has added a warning about necrotizing fasciitis of the perineum to SGLT2 inhibitor labels based on post-marketing reports across the class. The absolute risk is very low, and switching agents does not meaningfully change this risk; the warning applies to whichever SGLT2 inhibitor the patient is taking.

Drug interactions relevant to a switch decision

Dapagliflozin is metabolized primarily through UGT1A9 glucuronidation with limited CYP450 involvement, which the FDA label describes as reducing the likelihood of pharmacokinetic drug interactions (FDA label). Points relevant to a switch:

• Insulin or sulfonylureas. Switching between SGLT2 inhibitors while a patient remains on insulin does not itself require an insulin dose change, but if HbA1c is already near target, a modest insulin reduction is a reasonable clinical consideration to reduce hypoglycemia risk.
• UGT1A9 inducers such as rifampin. The label describes reduced dapagliflozin exposure with concurrent UGT1A9-inducing drugs. If a patient is switching to dapagliflozin while on such a medication, checking glycemic response at follow-up is reasonable.
• Loop diuretics. Covered above; volume status monitoring is the key action, not a formal drug interaction adjustment.

Reasons clinicians switch SGLT2 inhibitors

In practice, the decision to switch is rarely about pharmacology. The common drivers are:

1. Indication upgrade. A new heart failure or CKD diagnosis in a patient on an agent without that FDA-approved indication.
2. Formulary or cost. Insurance tier changes are a frequent, non-clinical driver of switching.
3. Tolerability. GI symptoms, more often reported with canagliflozin given its lower SGLT2 selectivity, can prompt a switch to a more selective agent.
4. Amputation risk concern. Some clinicians managing patients with peripheral arterial disease prefer to avoid canagliflozin given the CANVAS signal, while acknowledging that later analyses have not uniformly confirmed the size of that risk.

Heart failure guideline language from major US cardiology and heart failure societies recommends SGLT2 inhibitors for HFrEF regardless of diabetes status, without naming a preferred agent within the class; this leaves the choice of specific agent to the four factors above rather than to guideline mandate. The exact wording of current guideline recommendations should be checked against the current published guideline rather than a paraphrase, since guideline language is periodically updated.

A framework for the switch conversation and follow-up

This is an original decision-support framework for clinicians and patients discussing an SGLT2 inhibitor switch. It organizes the conversation into checkpoints, distinguishes what the FDA label actually specifies from what is individualized clinical judgment, and defines conditions that should pause or escalate the plan. It is a discussion aid, not a substitute for an individualized clinical assessment.

Checkpoint 1: Why is this switch happening? Label-specified fact: no SGLT2 inhibitor label requires a switch for any reason; every switch is elective. Judgment call: classify the reason as indication upgrade, cost/formulary, tolerability, or risk-factor avoidance (see list above). Document which one, because the monitoring plan differs. An indication upgrade (for example, a new heart failure diagnosis) deserves closer follow-up than a formulary swap between two agents with equivalent indications.

Checkpoint 2: Is the destination agent actually indicated for this patient's problem? Label-specified fact: FDA-approved indications differ across dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin (see comparison table above). Judgment call: if the patient has heart failure or CKD and the current agent lacks that indication, this is not a routine substitution; it should be documented as an indication-driven switch, and the clinician should confirm the new agent's dose matches what was used in the relevant outcome trial for that indication.

Checkpoint 3: Pre-switch labs and symptom screen Label-specified or trial-supported facts: eGFR threshold for the glycemic indication is specified in the label; DKA and volume depletion are recognized class risks. Judgment call: whether to also check potassium, ketones, or adjust a diuretic dose depends on the individual patient's renal function, diuretic regimen, and symptom history. There is no single lab panel mandated for every switch; the panel should be sized to the patient's risk factors.

Checkpoint 4: Timing of the switch itself Label-specified fact: no washout interval is specified. Judgment call: same-day or next-morning substitution is standard, but if the patient is acutely ill, dehydrated, or peri-operative, the switch should be deferred until the acute issue resolves, consistent with sick-day and perioperative guidance for the class as a whole.

Stop or escalate conditions to review with the patient before or after the switch:

• Nausea, vomiting, or unusual fatigue with or without elevated blood glucose: check ketones before continuing the new agent; if ketones are elevated, this is an urgent-care or emergency evaluation, not a routine follow-up call.
• Symptoms of volume depletion (dizziness on standing, reduced urination, confusion), particularly in a patient on loop diuretics: hold the new agent and contact the prescribing clinician promptly.
• eGFR drop that is large, sudden, or accompanied by symptoms, rather than the small early dip that is an expected hemodynamic response.
• Signs of a perineal or genital infection with pain, swelling, or rapid symptom progression: this warrants urgent evaluation given the rare but serious Fournier's gangrene warning across the class.
• Active, untreated UTI symptoms: treat before starting the new agent rather than switching through an active infection.

What this framework does not decide: it does not set an individual patient's target dose, does not replace an eGFR-based dosing decision made by the prescriber, and does not resolve indication-versus-cost trade-offs that depend on insurance coverage details specific to the patient. Those decisions belong to the treating clinician working directly with the patient's records.

Evidence boundary: what is established, what is plausible, what is not established

Established: All FDA-approved SGLT2 inhibitors share the same primary mechanism, the dapagliflozin label specifies no washout interval for switching within the class, and FDA-approved indications genuinely differ across agents (heart failure and CKD approval is not universal across the class).

Plausible but not directly tested in a dedicated trial: That overlapping two SGLT2 inhibitors for a period would meaningfully increase DKA or volume-depletion risk is a reasonable mechanistic inference, not a directly measured trial finding. That switching away from canagliflozin reduces an individual patient's amputation risk is plausible given the CANVAS signal but has not been demonstrated in a switch-specific study.

Not established: Head-to-head comparative outcome data between dapagliflozin and empagliflozin, or between any two SGLT2 inhibitors, for cardiorenal endpoints. Claims of clinical equivalence between agents rest on separately conducted placebo-controlled trials in different (though overlapping) populations, not on a direct comparison, and should be described that way rather than as proven interchangeability.

A note on sources for this draft

The original version of this article cited numbered PubMed identifiers for trial data and pharmacology claims. Those identifiers could not be independently verified as pointing to the correct papers for this draft, so precise figures (exact hazard ratios, confidence intervals, patient counts, selectivity ratios, and post-marketing case counts) have been removed or described in general terms rather than presented as sourced numbers. Anyone using this content for clinical documentation should confirm specific trial results directly against DAPA-HF, DAPA-CKD, EMPA-REG OUTCOME, EMPEROR-Reduced, CREDENCE, CANVAS, and VERTIS-CV as published, and confirm current label details directly against the FDA label below.